RSV Vaccine Attenuation Strategy To Delete M2-2 Protein Demonstrates Immunogenicity, May Be Worth Further Evaluation, Study Says

Infectious Disease Advisor (3/3, Masoud) reports, “The respiratory syncytial virus (RSV) vaccine attenuation strategy to delete M2-2 protein demonstrated immunogenicity and may be worth further evaluation, according to results of a study published in the...